At a conference in Rio de Janeiro last week, advocates from the Brazilian HIV charity Gestos described watching the collapse of American aid funding with something closer to recognition than surprise. They had tracked the tightening conditions attached to donor money since the early 2000s and drawn their conclusions years ago. Sovereignty over health financing determines whether a country's sickest citizens survive a change of government on the other side of the world, and Brazil built its HIV programme inside a constitutionally protected, domestically financed health system with that lesson already learned.

Britain has spent the past eighteen months on the donor side of that same story. The decision to cut official development assistance from 0.5 per cent of gross national income to 0.3 per cent by 2027, the steepest reduction among G7 nations, has redirected billions toward defence and away from the global health programmes that once carried British influence alongside them. Ministers describe the choice as an unavoidable response to a harder security environment. Whatever its merits, it places the United Kingdom among the retreating donors the Rio advocates were describing, its overseas health commitments now subject to the same fiscal weather they were cautioning others not to rely on.

The more searching question is what this pattern looks like when the mirror turns toward the NHS itself. Britain is, on paper, a wealthy and sovereign health system with no need of anyone's charity. Yet it has spent a decade accumulating its own version of the fragility Brazil's advocates were warning against, dependency dressed up as efficiency. The clearest example sits inside NHS England's digital infrastructure. The Federated Data Platform, built by a consortium led by the American firm Palantir, now underpins scheduling and discharge planning across a growing share of NHS trusts. A break clause falls due when the initial contract term ends in March 2027, and ministers, including the health minister Zubir Ahmed, have signalled openness to walking away if rivals can do the job better. That openness is itself telling. A health system does not seriously contemplate exiting infrastructure this central unless it has begun to worry about what it meant to hand that infrastructure to a single overseas contractor in the first place.

A similar worry runs through the medicines supply chain. Approximately 85% of the medications that the National Health Service (NHS) prescribes are off-patent, and many of their active ingredients are produced abroad, concentrated in a few foreign locations that are vulnerable to the exact kind of shock that a House of Lords committee had planned for earlier this year when it argued that the availability of medicines should be considered a national security issue. The government's life sciences sector plan gestures toward domestic manufacturing capacity, but the sector's own trade body has been blunt that the ambition has not yet caught up with the risk.

Britain is not comparable to a nation whose HIV program relied on USAID because of any of these.  The analogy should not be pushed further than it will bear. Yet the argument the Brazilian advocates were making in Rio, that resilience has to be built rather than borrowed, and that dependency on external actors eventually becomes a form of political exposure, applies with uncomfortable precision to a health system that has quietly let one American technology firm and a thin, concentrated pharmaceutical supply chain become load bearing. For NHS leaders weighing the Palantir break clause next year, and for a life sciences strategy still short on urgency, the warning is not coming from Washington. It has been building at home, one contract and one supply agreement at a time, and Rio simply gave it a name.